MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.
暂无分享,去创建一个
Inas S. Khayal | Soonmee Cha | Susan M. Chang | Sarah J Nelson | S. Vandenberg | S. Nelson | S. Cha | Kenneth J. Smith | T. Mcknight | Susan M Chang | Kenneth J Smith | Scott R Vandenberg | Tracy R McKnight | Inas S Khayal | Colleen P Cloyd | C. Cloyd
[1] M. J. van den Bent. New perspectives for the diagnosis and treatment of oligodendroglioma , 2001, Expert review of anticancer therapy.
[2] Inas S. Khayal,et al. Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas , 2009, NMR in biomedicine.
[3] Usha Sinha,et al. Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.
[4] K. Swanson,et al. Correlation of in vitro infiltration with glioma histological type in organotypic brain slices , 2004, British Journal of Cancer.
[5] Rebecca A Betensky,et al. Imaging Correlates of Molecular Signatures in Oligodendrogliomas , 2004, Clinical Cancer Research.
[6] P. Basser,et al. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.
[7] D B Vigneron,et al. Registration of images from sequential MR studies of the brain , 1994, Journal of magnetic resonance imaging : JMRI.
[8] M. Berger,et al. Coregistration Accuracy and Detection of Brain Shift Using Intraoperative Sononavigation during Resection of Hemispheric Tumors , 2003, Neurosurgery.
[9] N. Probst-Hensch,et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.
[10] A. von Deimling,et al. Molecular pathology of oligodendroglial tumors. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[11] K. Kono,et al. The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.
[12] J. Cairncross,et al. PCV for Oligodendroglial Tumors: In Search of Prognostic Factors for Response and Survival , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[13] L. Deangelis,et al. Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.
[14] Stephen M. Smith,et al. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.
[15] David W. Smith,et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.
[16] D. Bihan,et al. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? , 1998 .
[17] R. Jenkins,et al. Genetic alterations and chemotherapeutic response in human diffuse gliomas , 2001, Expert review of anticancer therapy.
[18] D. Le Bihan. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? , 1998, Radiology.
[19] M. Bent. New perspectives for the diagnosis and treatment of oligodendroglioma. , 2001 .
[20] Inas S. Khayal,et al. Characterization of low‐grade gliomas using RGB color maps derived from ADC histograms , 2009, Journal of magnetic resonance imaging : JMRI.
[21] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[22] D. Louis,et al. Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.
[23] B. Scheithauer,et al. Oligodendrogliomas: the Mayo Clinic experience. , 1992, Journal of neurosurgery.
[24] J. Buckner,et al. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Vigneron,et al. An automated technique for the quantitative assessment of 3D‐MRSI data from patients with glioma , 2001, Journal of magnetic resonance imaging : JMRI.
[26] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[27] G. Krol,et al. Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.
[28] Hiroyuki Aburatani,et al. Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with Chromosome 1p Loss , 2004, Brain pathology.
[29] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[30] Rebecca A Betensky,et al. Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.
[31] Paul S Tofts,et al. Apparent diffusion coefficient histograms may predict low‐grade glioma subtype , 2007, NMR in biomedicine.
[32] Carol Walker,et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. , 2006, Brain : a journal of neurology.